Moderna rebounds 2.9% premarket as Barclays lifts PT to $125
MRNA Moderna Inc
$138.89 -4.30%
View chart & analysis → - 1Moderna (MRNA) rises 2.9% in premarket, recovering part of recent losses after cancer vaccine boost
- 2Barclays raises price target to $125 from $48 on Intusmeran Phase 3 results
- 3First late-stage success for personalized mRNA cancer vaccine; shares up ~392% YTD, now consolidating
This 3-line summary is compiled from the report below.
Barrons.com +1 View original ↗
오늘의 AI 픽 5종목, 무료로 전부 공개합니다숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다